TransPharma Medical has changed the name of its drug delivery system ViaDerm to ViaDor.
TransPharma’s ViaDor drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch.
ViaDerm consists of a reusable battery-operated handheld electronic control unit, a disposable microelectrode array that is employed in conjunction with a patch containing a drug and it allows patients to apply the patch with one hand in a user friendly manner.
TransPharma claims ViaDor provides a cost-effective, easy-to-use, virtually pain-free, self-administered solution that enables the safe, reproducible and accurate delivery of a range of product candidates, including hydrophilic small molecule such as peptides and proteins.
TransPharma CEO Daphna Heffetz said the new name that they have chosen for their transdermal drug delivery system is a natural consequence of TransPharma’s increasing success and expansion.
"The ViaDor system is currently being studied in advanced-stage clinical trials for three distinct drug products: ViaDor-hPTH (1-34) for the treatment of osteoporosis, in collaboration with Eli Lilly; ViaDor-GLP1 agonist for the treatment of type II diabetes; and ViaDor-Calcitonin for the treatment of musculoskeletal diseases," Heffetz said.